Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 5, 2012, Pages 529-537

  Naoulou, Becky ^a   Tsai, Ming C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

idiopathic and non functional heavy menstrual bleeding; menstrual blood loss; Tranexamic acid

Indexed keywords

4 AMINOMETHYLCYCLOHEXANECARBOXYLIC ACID 1 [(ETHOXYCARBONYL)OXY]ETHYL ESTER; DICLOFENAC; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NORETHISTERONE; PLACEBO; PRODRUG; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLOOD VOLUME; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; IDIOPATHIC DISEASE; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA;

ANTIFIBRINOLYTIC AGENTS; FEMALE; HUMANS; MENORRHAGIA; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84860238434     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01361.x     Document Type: Review

References (29)

1. National Institute for Health and Clinical Excellence. NICE clinical guideline 44: heavy menstrual bleeding. London, UK: National Health Service; January 2007.
2. Hallberg I, Högdahl AM, Nilsson L, Rybo G., Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966; 45: 320-51.
3. Oehler MK, Rees MC,. Menorrhagia: an update. Acta Obstet Gynecol Scand. 2003; 82: 405-22.
4. Clarke A, Black N, Rowe P, Mott S, Howle K., Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol. 1995; 102: 611-20.
5. American College of Obstetricians and Gynecologists. Alternatives to hysterectomy in the management of leiomyomas. ACOG practice bulletin no. 96. Obstet Gynecol. 2008; 112: 387-400.
6. Coulter A, Peto V, Jenkinson C., Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract. 1994; 11: 394-401.
7. Ido K, Neo M, Asada Y., Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg. 2000; 120: 518-20.
8. Wellington K, Wagstaff AJ,. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003; 63: 1417-33.
9. Stein K, Ascher-Walsh C., A comprehensive approach to the treatment of uterine leiomyomata. Mt Sinai J Med. 2009; 76: 546-56.
10. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al,. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001; 20: 21-35.
11. Callender ST, Warner GT, Cope E., Treatment of menorrhagia with tranexamic acid. A double blind trial. Br Med J. 1970; 4: 214-6.
12. Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B., Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol. 1995; 102: 913-7.
13. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al,. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010; 116: 865-75.
14. Preston JT, Cameron IT, Adams EJ, Smith SK,. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995; 100: 401-5.
15. Weström L, Bengtsson LP,. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. J Reprod Med. 1970; 5: 154-61.
16. Bonnar J, Sheppard B., Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996; 313: 579-82.
17. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S., Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006; 26: 673-8.
18. Ylikorkala O, Viinikka L., Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol. 1983; 90: 78-83.
19. Lakhani KP, Marsh MS, Purcell W, Hardiman P., Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid. Ultrasound Obstet Gynecol. 1998; 11: 283-5.
20. Winkler UH,. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol. 2001; 99: 238-43.
21. Rybo G., Tranexamic acid therapy: effective treatment in heavy menstrual bleeding: clinical update on safety. Therapeutic Advances. 1991; 4: 1-8.
22. Berntorp E, Follrud C, Lethagen S., No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001; 86: 714-5.
23. Lethaby A, Farquhar C, Cooke I., Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4): CD000249.
24. Barbieri RL,. A new (to the US) first-line agent for heavy menstrual bleeding (Editorial). OBG Management. 2010; 22: 9-12.
25. Nilsson L, Rybo G., Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). A double blind investigation. Acta Obstet Gynecol Scand. 1967; 46: 572-80.
26. Pihlbrant A, Schannong M, Vessman J., Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981; 20: 65-72.
27. Svahn CM, Schannong M, Stenberg U, Widlund L., Absorption of tranexamic acid as a prodrug in healthy volunteers. Arzneim-Forsch Drug Res. 1988; 38: 735-8.
28. Hillier K, Kasonde JM,. Prostaglandin E and F concentrations in human endometrium after insertion of intrauterine contraceptive device. Lancet. 1976; i: 15-6.
29. Kasonde JM, Bonnar J., Effect of ethamsylate and aminocaproic acid on menstrual blood loss in women using intrauterine devices. British Medical Journal. 1975; 4: 21-2.